NCT00463814 is a Phase 1 clinical trial of AZD6244 in Tumor, sponsored by AstraZeneca.

Who is sponsoring NCT00463814?

NCT00463814 is sponsored by AstraZeneca.

What drugs are being tested in NCT00463814?

Interventions in NCT00463814: AZD6244.

What condition does NCT00463814 study?

NCT00463814 studies Tumor, Cancer.

Is NCT00463814 still recruiting?

NCT00463814 is currently active, enrolled. Last updated 13 November 2025.

Last reviewed 2025-11-13 · How we verify

NCT00463814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Active, enrolled Phase 1 Last updated 13 November 2025

What this trial tests

Phase 1 trial testing AZD6244 in Tumor in 58 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 March 2007

Primary endpoint
17 June 2008

31 December 2025

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	8 March 2007
Primary completion	17 June 2008
Estimated completion	31 December 2025
Sites	4 locations across United Kingdom, Netherlands, United States

Drugs / interventions tested

AZD6244 — full drug profile →

Conditions studied

Tumor — all drugs for Tumor →
Cancer — all drugs for Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 99, any sex, with Tumor or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.
Campagne O, Yeo KK, Fangusaro J, Stewart CF. · · 2021 · cited 35× · PMID 33354735 · DOI 10.1007/s40262-020-00967-y
(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.
Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, et al · · 2012 · cited 7× · PMID 23372439 · DOI 10.4103/1450-1147.103413
Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers.
Mughees M, Tacam M, Tan AW, Pitner MK, et al · · 2025 · cited 2× · PMID 40358476 · DOI 10.1158/1535-7163.mct-24-0593

Verify or expand the search:

Other trials of AZD6244

Trials testing the same drug.

NCT01362803 — AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors · Phase 1, PHASE2 · active not recruiting
NCT01248247 — BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small C · Phase 2 · completed
NCT01306045 — Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Mal · Phase 2 · completed
NCT01287130 — AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer · Phase 1 · completed
NCT01229150 — Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS W · Phase 2 · completed

Other recruiting trials for Tumor

Currently open trials in the same condition.

NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
NCT07147465 — Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for On · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00463814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 13 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00463814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing